Brief: LTR Pharma Says Oroflow Becomes First GI Application Of Intranasal Platform
24/06/2026 02:38
BRIEF-LTR Pharma Says Oroflow Becomes First GI Application Of Intranasal Platform June 24 (Reuters) - LTR Pharma Ltd LTP.AX:
OROFLOW BECOMES FIRST GI APPLICATION OF LTR PHARMA INTRANASAL PLATFORM IN CLINICAL EVALUATION
Further company coverage: LTP.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ltr Pharma
See all newsAustralia's LTR Pharma surges as its drug begins US prescription fulfillment
Brief: LTR Pharma Executes Exclusive Pilot Agreement With Marius Pharmaceuticals, Inc For Kyzatrex
Brief: LTR Pharma Executes U.S. Commercial Agreement With Strive
Australia's LTR Pharma rises on commercial tie-up with US telehealth firm
Australia's LT Pharma gains after nod to test nasal spray